Lunai Bioworks (LNAI) Change in Receivables (2013 - 2026)
Lunai Bioworks (LNAI) recorded quarterly Change in Receivables of $62079.0 in Q1 2026, up 3447.37% quarter-over-quarter from $1750.0 in Q4 2025, and up 2867.45% on a YoY basis from $2092.0 in Q1 2025.
Lunai Bioworks (LNAI) Change in Receivables (2013 - 2026) Analysis & Trends
Lunai Bioworks' Change in Receivables history runs 13 years deep, the most recent figure standing at $62079.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 2867.45% year-over-year to $62079.0; the TTM figure through Mar 2026 stood at -$96662.0 (down 179.64% YoY), while the FY2025 annual figure was -$1.2 million, down 204.11% from the prior year.
- Change in Receivables was $62079.0 for Q1 2026 at Lunai Bioworks, up from $1750.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.1 million in Q2 2024 to a low of -$1.2 million in Q4 2024.
- Historically, Change in Receivables has averaged $2246.8 across 4 years, with a median of $2092.0 in 2025.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables sank 115.06% in 2025, then jumped 2867.45% in 2026.
- A 4-year view of Change in Receivables shows it stood at -$4034.0 in 2022, then slumped by 29273.4% to -$1.2 million in 2024, then jumped by 100.15% to $1750.0 in 2025, then jumped by 3447.37% to $62079.0 in 2026.
- The last three Change in Receivables figures came in at $62079.0 (Q1 2026), $1750.0 (Q4 2025), and $6407.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 | 62,079.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,079.00 |
| Mar 31, 2026 | 62,079.00 |
| Dec 31, 2025 | 1,750.00 |
| Dec 31, 2025 | 1,750.00 |
| Sep 30, 2025 | 6,407.00 |
| Sep 30, 2025 | 6,407.00 |
| Jun 30, 2025 | -166,898.00 |
| Jun 30, 2025 | -166,898.00 |
| Mar 31, 2025 | 2,092.00 |
| Mar 31, 2025 | 2,092.00 |
| Dec 31, 2024 | -1.18 Mn |
| Dec 31, 2024 | -1.18 Mn |
| Sep 30, 2024 | 195,961.00 |
| Sep 30, 2024 | 195,961.00 |
| Jun 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Dec 31, 2022 | -4,034.00 |
| Dec 31, 2022 | -4,034.00 |
| Sep 30, 2022 | 3,988.00 |
| Sep 30, 2022 | 3,988.00 |